Global Blood Therapeutics (GBT) Presents Significant Data from Phase 1/2 GBT440-00 Study at ASH 2016
Tweet Send to a Friend
Global Blood Therapeutics, Inc. (GBT) (Nasdaq: GBT) announced the presentation of results from its ongoing Phase 1/2 GBT440-001 study that ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
